Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573685 · ClinicalTrials.gov registry record · NA
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
A NA study of Rheumatoid Arthritis and Fibromyalgia, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT05573685: Completed NA study of Rheumatoid Arthritis and Fibromyalgia, sponsored by Click Therapeutics.
NCT05573685 is a NA study of Rheumatoid Arthritis and Fibromyalgia that has completed, run by Click Therapeutics. The registered enrollment target is 124 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05573685, a NA study of Rheumatoid Arthritis and Fibromyalgia, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).
Primary Outcome
Effect size change as measured by the Numerical Rating Scale (NRS) questionnaire, from the lowest (0) to the highest (10)
Conditions Studied
Interventions
- DEVICE DiNaMo Study App
- DEVICE Placebo App
Study Locations (1)
New York
- Click Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2023-02-06 |
| Phase | NA |
What the finished NCT05573685 record still lists
NCT05573685 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which DiNaMo Study App is the first listed.
NCT05573685 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05573685 about?
NCT05573685 is a clinical study titled "Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training". CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).
What is the current status of trial NCT05573685?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2022-10-10. Estimated completion is 2023-02-06.
What conditions does trial NCT05573685 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Fibromyalgia, Irritable Bowel Syndrome, Diabetic Neuropathy.
What interventions are being tested in trial NCT05573685?
The interventions under investigation include: DiNaMo Study App (DEVICE), Placebo App (DEVICE).
Who is sponsoring clinical trial NCT05573685?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05573685 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05573685's enrollment target sits among peer trials
124 108th of 197 higher than 89 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis
RECRUITING · NA
-
Improving Hypertension Control in Rheumatoid Arthritis
RECRUITING · NA
-
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04959695 · 124 participants · NA
Evaluation of the PE Coach Mobile Application Among Veterans With PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI